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Background: MicroRNAs are small RNA molecules that regulate the translation of protein from gene transcripts and
are a powerful mechanism to regulate gene networks. Next-generation sequencing technologies have produced
important insights into gene transcription changes that occur in the brain of individuals diagnosed with autism
spectrum disorder (asd). However, these technologies have not yet been employed to uncover changes in microRNAs
in the brain of individuals diagnosed with asd.
Methods: Small RNA next-generation sequencing was performed on RNA extracted from 12 human autism brain
samples and 12 controls. Real-time PCR was used to validate a sample of the differentially expressed microRNAs, and
bioinformatic analysis determined common pathways of gene targets. MicroRNA expression data was correlated to
genome-wide DNA methylation data to determine if there is epigenetic regulation of dysregulated microRNAs in the
autism brain. Luciferase assays, real-time PCR, and Western blot analysis were used to determine how dysregulated
microRNAs may regulate the expression and translation of an autism-related gene transcript.
Results: We determined that miR-142-5p, miR-142-3p, miR-451a, miR-144-3p, and miR-21-5p are overexpressed in the
asd brain. Furthermore, the promoter region of the miR-142 gene is hypomethylated in the same brain samples,
suggesting that epigenetics plays a role in dysregulation of microRNAs in the brain. Bioinformatic analysis revealed that
these microRNAs target genes that are involved in synaptic function. Further bioinformatic analysis, coupled with
in vitro luciferase assays, determined that miR-451a and miR-21-5p can target the oxytocin receptor (OXTR) gene. OXTR
gene expression is increased in these same brain samples, and there is a positive correlation between miR-21-5p and
OXTR expression. However, miR-21-5p expression negatively correlates to production of OXTR protein from the OXTR
transcript. Therefore, we suggest that miR-21-5p may attenuate OXTR expression in the human autism brain.
Conclusions: Our data suggests that dysregulation of microRNAs may play a biological role in the brain of individuals
of autism. In addition, we suggest an interaction between epigenetic mechanisms and microRNA dysregulation in the
brain. Overall, this data adds an important link in our understanding of the molecular events that are dysregulated in
the brain of individuals diagnosed with autism.
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Autism spectrum disorder (asd) is a neurodevelopmental
disorder that includes disruptions in social behavior,
communication, and stereotypic behaviors [1]. While a
plethora of scientific research has indicated that both
genetic and unknown factors have primary roles in the
etiology of autism [2, 3], there is still scarce knowledge
of the precise molecular mechanisms that are respon-
sible for autistic behavior.
Recent studies have focused on molecular changes in
the frontal cortex of individuals diagnosed with autism.
Voineagu et al., using a whole genome transcriptome
approach, determined the downregulation of many tran-
scripts encoding synaptic proteins and the overexpression
of many transcripts encoding immune system proteins in
the frontal cortex of individuals with autism [4]. A separate
whole genome RNA sequencing study recently found a
similar overexpression of immune system-related gene
transcripts in a separate autism brain cohort [5]. Using a
whole genome approach, we have previously demonstrated
epigenetic differences on genomic regions responsible for
synaptic transmission and immune regulation in the frontal
cortex of individuals with autism [6]. Therefore, gene
transcription dysregulation in the brain of individuals diag-
nosed with asd may partially be due to epigenetic modifica-
tions. However, there are several other gene transcription
and translation regulatory pathways that have yet to be
probed for dysregulation in the brain of individuals with
asd. Research into these mechanisms is necessary in order
to produce a complete picture of molecular dysregulation
in the brain of individuals with asd.
MicroRNAs are small regulatory nucleotides that inhibit
translation of target messenger RNAs. MicroRNA are
approximately 21 bases, and form complexes with the
RNA-induced silencing complex (RISC), which includes
Dicer and a member of the Argonaute family of proteins
[7]. The RISC-microRNA complex then binds target mes-
senger RNAs that are complementary at the “seed region”
of the microRNA, typically nucleotides 2–8 [8]. The bind-
ing to messenger RNAs will lead to decreased protein
translation, either through degradation of the target mRNA
or the inhibition of protein translation through compart-
mental storage of mRNA complexes [9, 10]. While it is yet
to be determined the exact number of microRNAs that are
expressed in the human genome, there are currently up to
1881 putative human microRNA precursors and 2588
putative mature microRNAs in the miRBase database
[11], and each microRNA may target multiple mRNAs.
Therefore, microRNA upregulation or downregulation may
influence entire protein networks, and is a uniquely power-
ful regulatory mechanism.
Previous research has determined dysregulation of
microRNAs in the brain in various psychiatric conditions
[12], including schizophrenia [13] and Huntington’s disease[14]. Dysregulation of serum microRNAs have been de-
tected in individuals with autism [15]. The authors un-
covered a list of dysregulated microRNAs that target
mRNAs involved in the biological process of axon guid-
ance. One previous study looked at differences in
microRNAs in the human autism brain using microarray
technology [16]. They did not detect any microRNAs that
were differentially expressed between control and autism
brains, although they detected several microRNAs that
had a higher variation of expression in the autism cohort.
However, no study has previously been reported on
dysregulation of microRNAs in the human autism brain
by using next-generation sequencing technologies, which
are capable of detecting all microRNAs in the sample, and
have a significantly higher sensitivity. In this current work,
using next-generation sequencing followed by real-time
PCR, we determined significant upregulation of multiple
microRNAs in the brain of individuals with asd. Further
analysis revealed that microRNA upregulation may have a
very relevant impact on biological pathways involved in
autism, both by targeting oxytocin receptor expression
and targeting several gene ontology pathways that are
relevant to autism, including synapse function and signal
transduction. In addition, we suggest a connection between
DNA methylation dysregulation and the overexpression of
miR-142 in autism. Overall, our data provides evidence for




Brain tissue samples from 12 autism cases and 12 controls
were obtained from the Autism Tissue Program (ATP).
All of these samples were received from the Harvard Brain
Bank except for two brain samples of individuals with asd,
which were obtained from the UK Brain Bank for Autism
(University of Oxford). Brodmann’s area 10 was used in
this analysis, and information about samples is found in
Additional file 1. Full clinical information about the in-
dividuals, when available, is provided upon request
(http:www.autismtissueprogram.org). The experimenta-
tion on these samples was given ethical approval
through the Bar Ilan University Institutional Review
Board (Helsinki Committee), and patient or parental
consent was given to the Autism Tissue Program for all
individuals tested in this study.
Total RNA extraction and generation of small RNA
libraries
Total RNA was extracted from approximately 70 mg of
liquid nitrogen pulverized tissue using the miRNeasy kit
and treated with RNase-Free DNase (Qiagen). For each
brain sample, 1 μg of RNA was used to construct se-
quencing libraries using Illumina’s TruSeq Small RNA
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(Illumina, San Diego, CA). In brief, small RNA molecules
were adapter-ligated, reverse transcribed, PCR amplified,
and gel purified to generate the library. Multiplexed sam-
ples were equimolarly pooled into sets of 24 samples per
flow cell lane and sequenced using 1 × 50 bp single-end
reads on Illumina’s MiSeq system at Bar Ilan University
Faculty of Medicine sequencing core facility. Samples
were sequenced twice to obtain a high read count.
Demultiplexing and FASTQ file generation (raw se-
quence read plus quality information in Phred format)
were done using Illumina’s Consensus Assessment of
Sequence and Variation (CASAVA) pipeline.Alignment of miRNA-seq reads and differential expression
analysis
FASTQ files were uploaded to the miRanalyzer web-based
tool for mapping small RNAs to the miRBase database.
miRanalyzer uses the short-read aligner bowtie to align to
the reference database [17]. Parameters used included a
minimum match seed length of 17 base pairs with a max-
imum of one mismatch within this region. After identifying
all possible matches with a minimum 17 base pair match,
the longest match was chosen as the identified microRNA.
This produced small RNA transcription maps, with read
counts, for each sequencing library. Normalized read
counts were created using DESeq [18], where a scaling
factor was computed as the median of the ratio, of each
microRNA, of its read count over its geometric mean
among all samples. Each sample’s count was then divided
by this scaling factor. The normalized reads can be found
in Additional file 2. To analyze for differential expression
between the different experimental groups, the transcrip-
tion maps were loaded onto the miRanalyzer differential
expression tool. This tool is based on the DESeq package,
which produces a differential expression for each iden-
tified microRNA, with the appropriate fold changes,
p value, and FDR-adjusted p value.microRNA quantitative PCR
Total RNA from each sample was reverse transcribed
with the miScript II RT Kit. Real-time PCR was then
performed with the miScript SYBER Green PCR kit, ac-
cording to the manufacturer’s protocols. A specific forward
primer was used for each microRNA, together with a
universal reverse primer. Specific primers used are in
Additional file 3. U6 snRNA was used as the house-
keeping gene in these experiments. All PCR reactions
were performed on the ViiA™ 7 Real-Time PCR System.
Real-time PCR reactions were performed on all samples
used in the sequencing, excluding one autism individual
(UK20119, Additional file 1: Table S1), which we only
had enough RNA sample for sequencing.Methylation pyrosequencing
Pyrosequencing technology was used to further validate
differences in DNA methylation detected with Infinium
HumanMethylation450 BeadChip. We tested three CpG
sites in the promoter of microRNA-142. DNA samples
were submitted to the School of Medicine and Dentistry
Genome Centre Barts and London (London, UK) and
processed by the following procedure. Briefly, 500 ng
DNA from each individual was treated with sodium
bisulphite using the EZ96-DNA methylation kit ac-
cording to the manufacturer’s recommendation, and
amplified by a bisulphite-polymerase chain reaction.
Quantitative DNA methylation analysis of each CpG
was conducted using PSQ96 Pyrosequencer (Qiagen,
Valencia, CA, USA) [19]. In short, a biotinylated PCR
product was created from the genomic region and
hybridized to a sequencing primer. The PCR product
was incubated with DNA polymerase, luciferase, ATP
sulfurylase, APS, and luciferin. After the addition of a
nucleotide to the reaction, the release of a diphosphate
group will induce the generation of light, which is read
by the Pyrosequencer. The amount of light relates to
the amount of that particular nucleotide found at that
genomic region. For a more detailed protocol, please
refer to Kreutz et al. [19]. All samples were analyzed,
excluding AN12137 (control sample, Additional file 1:
Table S1), because DNA from this sample did not pass
the pyrosequencing quality control checks.
Messenger RNA real-time PCR
Real-time PCR was performed on an ABI ViiA™ 7 Real-
Time PCR detection system in 10 μl volume containing
FastStart Universal SYBR Green Master (Roche) and
primers at a concentration of 0.250 μM each. All
primers used were designed using Primer-BLAST and
tested for the efficiency through a standard curve. All
primer sequences are listed in Additional file 3. The
strategy used for the normalization of quantitative RT-
PCR data from human genes was geometric averaging
of multiple internal control genes according to the
Vandesompele et al.’s method [20]. We used three
housekeeping genes (GAPDH, HPRT1, and POLR2a)
that represent an accurate control for mRNA expres-
sion analysis of postmortem brain samples. For each
housekeeping gene, we measured the gene stability
(M value) and ranked it using the geNorm algorithm.
Construction of psiCHECK2-3′UTR construct for luciferase
assays
Oxytocin receptor (OXTR) 3′ UTR sequence was PCR
amplified from human genomic DNA (primers: 5′-
TTCCACAGCATCAAGCAGTC-3′ and 5′-CCCAGCA
GAGTGAACGTCTT-3′). PCR fragment was digested
with Not1 and Xho1 and ligated into the psiCHECK2
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the same restriction enzymes. The 3′ UTR of OXTR was
cloned directly downstream of the Renilla luciferase gene
in the psiCHECK2 plasmid, which also contains the
Firefly luciferase gene as an internal control. Cloning
orientation was verified by sequencing. Plasmids ex-
pressing miR-451a, miR-21-5p, and miR-7 and plasmid
expressing only GFP were purchased from OriGene
(Rockville, MD, USA). Plasmids expressing microRNAs
also express GFP.
Transfections and luciferase assay in HEK293T cells
Cells were grown in a 24-well format to a 70–85 % con-
fluency and transfected using polyethyleneimine (Sigma,
St. Louis, MI, USA) with the following plasmids: 100 ng
of psiCHECK2-3′ UTR plasmid and 400 ng of pEGFP–
miR-451a, pEGFP– miR-21-5p, pEGFP– miR-7, or
empty pEGFP overexpression plasmids. At 72 h after
transfection, cells were lysed, and luciferase reporter ac-
tivity was assayed as described previously [21]. Renilla
luciferase values were normalized to control firefly lucif-
erase levels and averaged across three-well repetitions
per condition. Data presented are the average of three
experiments.
Western blot
Brain tissue was homogenized in a tissue lysis buffer
containing 50 mM Tris-HCl (pH 7.5), 150 mM KCl, and
0.32 M sucrose supplemented with protease inhibitor
cocktail (Sigma). Protein estimation was done with
Bradford reagent (Sigma, St. Louis, MI, USA). Samples
(20 μg) were subjected to SDS-PAGE and transferred
onto a nitrocellulose membrane. The membrane was
blocked for 1 h in PBS with Tween 20 and 5 % non-fat
milk followed by overnight incubation with a primary
antibody in 5 % BSA. The primary antibodies used
were the following: anti-OXTR (1:1000 R&D Systems,
Minneapolis, MS, USA) and anti-Hsc70 rabbit serum
(1:1000, previously described [22]). Following washing,
the membranes were incubated with LI-COR dye-
conjugated secondary antibody for 1 h. Membranes
were then scanned on the LI-COR Odyssey scanner.
The intensity of the bands was quantified using LI-
COR imaging software, and OXTR protein levels were
normalized against the Hsc70 protein levels.
Statistics
All statistical analyses, including t tests and Spearman’s
correlation analysis, on real-time PCR and pyrosequenc-
ing methylation data were performed with SPSS software
package (version 20.0; SPSS, Chicago, IL, USA). We used
two-tailed independent t test for groups with equal vari-
ance of distribution, unless otherwise noted.Results
Identification of differentially expressed microRNAs in the
brain of individuals diagnosed with asd
In order to determine changes in microRNA expression in
the brain of individuals diagnosed with autism, we studied
postmortem brain samples from 12 individuals with an
ADIR-R-confirmed diagnosis of autism and 12 matched
controls. All samples were from Brodmann area 10, a sub-
component of the frontal cortex, which was previously ex-
amined for differences in DNA methylation between
controls and individuals with autism [6]. Extensive informa-
tion about these samples, including age and sex, are found
in Additional file 1. There are no significant differences in
age between the control and autism samples, and there is
one female in the control group compared to two in the
autism group. There is a relatively wide range of ages in
both the control and autism groups, reflecting the current
availability of human autism brain tissues. However, all
brain samples are from adult individuals, therefore exclud-
ing the variability of working with tissues from different de-
velopmental time points. Following total RNA extraction
and small RNA sequencing library preparation, the libraries
were sequenced on the MiSeq Illumina high throughput se-
quencer. The miRanalyzer tool was used to map sequenced
read and to identify microRNAs that were differentially
expressed between the two experimental groups [17]. Ac-
cording to this initial analysis, 23 microRNAs were
found to be differentially expressed between the con-
trol and autism groups (FDR < 0.05), including 18
microRNAs that were upregulated in the autism group,
and five microRNAs that were downregulated in the
autism group (Table 1).
In order to identify individual microRNAs with a high
confidence of dysregulation in the autism samples, we
employed real-time PCR to detect the levels of the top
15 differentially expressed microRNAs in the same brain
samples. Of these microRNAs we studied, real-time
PCR analysis detected significant upregulation of five
microRNAs (Fig. 1), including miR-142-5p (p = 0.0003),
miR-142-3p (p = 0.003), miR-21 (p = 0.022), miR-451a
(p = 0.007), and miR-144-3p (p = 0.0001). Two additional
microRNAs were significantly upregulated when applying a
one-tailed t test. The inability to validate more of the
microRNAs found in the sequencing analysis may partly be
a consequence of the relatively lower sensitivity and specifi-
city of the real-time PCR method, in comparison to the se-
quencing method, although we cannot dismiss the
possibility of false positives in the sequencing results. We
note that dysregulation of a 5p form of the microRNA does
not mean there is a dysregulation of the 3p form, and vice
versa, which is due partly to the fact that both forms are
not always expressed in the same tissue. All of our add-
itional analysis was performed on the five microRNAs that
are verified as upregulated using the two-tailed analysis.
Table 1 List of differentially expressed microRNAs according to whole RNA sequencing analysis
ID Control mean Autism mean Fold change pval padj
hsa-miR-338-5p 195.14 866.47 4.44 5.47E−81 6.04E−78
hsa-miR-3168 1.79 16.51 9.23 3.07E−30 1.70E−27
hsa-miR-451a 797.35 1841.5 2.31 7.30E−20 2.69E−17
hsa-miR-21-5p 571.1 1304.5 2.28 1.34E−15 3.69E−13
hsa-miR-7-5p 131.07 309.53 2.36 4.85E−15 1.07E−12
hsa-miR-21-3p 20.9 60.5 2.89 3.40E−11 6.26E−09
hsa-miR-142-5p 9.69 26.67 2.75 2.03E−08 3.21E−06
hsa-miR-142-3p 3.68 10.97 2.98 2.34E−06 0.0003
hsa-miR-19a-3p 4.83 13.71 2.84 3.74E−06 0.0005
hsa-miR-211-5p 14.67 3.04 0.2071 4.12E−06 0.0005
hsa-miR-19b-3p 45.41 97.86 2.16 4.61E−06 0.0005
hsa-miR-219-5p 75.57 144.72 1.91 1.04E−05 0.001
hsa-miR-144-3p 2.25 7.73 3.43 1.25E−05 0.0011
hsa-miR-137 68.05 125.42 1.84 1.96E−05 0.0015
hsa-miR-34a-5p 81.74 47.38 0.5797 5.52E−05 0.0041
hsa-miR-146a-5p 72.06 121.44 1.69 8.27E−05 0.0054
hsa-let-376c-3p 23.28 44.75 1.92 8.00E−05 0.0054
hsa-let-7a-5p 18985.7 12852 0.6769 0.0004 0.0205
hsa-miR-379-5p 37 65.13 1.76 0.0003 0.0205
hsa-miR-92b-3p 2911.42 1957 0.6722 0.0008 0.0441
hsa-miR-3960 66.41 30.22 0.4551 0.0008 0.0441
hsa-miR-494 3.01 6.37 2.12 0.0009 0.0443
hsa-miR-155-5p 16.16 30.14 1.88 0.0009 0.0443
Fig. 1 miR-451a, miR-142-5p, miR-142-3p, miR-144-3p, and miR-21-5p
are overexpressed in the autism brain samples. Real-time PCR was
performed on the first 15 microRNAs from the list in Table 1. The data is
represented as box plots, with each dot representing an individual brain
sample. The line identifies mean, and red and purple areas represent
standard error of the means and standard deviation, respectively. In the
x-axis, C = control and A = autism. Two-tailed students t tests *p< 0.05,
**p< 0.01, ***p< 0.001. #p< 0.05 in one-tailed students t test
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methylation of its promoter region in the brain of
individuals diagnosed with asd
In a previous study, we used the Illumina 450K methylation
array to identify changes in DNA methylation at the
genome-wide level in the same brain samples [6]. We com-
pared our data from this current study to the list of differ-
entially methylated CpG sites in the previous study. Of
great interest, five CpGs in the promoter region of the
miR-142 gene were hypomethylated in the autism
brain samples, according to the microarray analysis
(Fig. 2a, b). These include three CpGs that are found
within ten nucleotides of the transcription start site for
miR-142 (marked in red in Fig. 2a). No CpGs were dys-
regulated in the genetic regions encoding miR-21,
miR-144, or miR-451 [6]. Subsequently, we used pyrose-
quencing, an independent method for quantifying DNA
methylation, to determine the DNA methylation level of
these three CpGs at the transcription start site (Fig. 2c).
Pyrosequencing confirmed that there is a significant
decrease of DNA methylation of these three CpGs in
the autism brain. In addition, Spearman’s correlation ana-
lysis found a significant inverse correlation between the
methylation levels at each specific CpG and expression
Fig. 2 Promoter of miR-142 is hypomethylated in autism brain. a Scheme of nucleotide sequence directly surrounding the transcription start
site (TSS) of miR-142. Three CG dinucleotides found directly upstream of TSS are highlighted in red. b DNA methylation microarray analysis
of miR-142 gene, showing five CpGs that are significantly hypomethylated. c Pyrosequencing analysis of the three CpGs directly upstream
of the TSS of miR-142. *p value <0.05, **p value <0.01. One-tailed t test. d–f Spearman’s correlation coefficient, including p value between
miR-142-5p gene expression and DNA methylation. Each graph represents a correlation between miR-142-5p and a separate CpG site that
was analyzed by pyrosequencing
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(Additional file 4). Therefore, we can directly correlate be-
tween decreased methylation of the miR-142 promoter and
increased expression of the miR-142 transcripts in the brain
samples of individuals diagnosed with asd. These results
suggest a role for epigenetic dysregulation in miR-142 over-
expression in the autism brain samples.
Gene ontology analysis
To gain further insight into the biological meaning of the
dysregulation of miR-142-5p, miR-142-3p, miR-21-5p, miR-
144-3p, and miR-451a in the autism brain samples, we per-
formed gene ontology analysis on the targets of these
microRNAs, using the DIANA-lab software [23]. Several
categories were enriched, particularly in categories related
to signal transduction (mTOR signaling, ErbB signaling,
MAPK signaling, etc.), synaptic categories (dopaminergic
synapse, axon guidance, glutamatergic synapse, seroto-
nergic synapse, neurotrophin signaling pathway), and
many cancer-related categories (Fig. 3). Considering that
recent data have implicated inflammatory processes in theetiology of autism [24–26], the gene ontology category of
TGF-beta signaling may also be very relevant to asd.
miR-21-5p and miR-451a target the oxytocin receptor
gene
To gain more insight into interesting individual mRNAs
that are targets of more than one of our microRNAs, we
employed the microRNA target resource at microrna.org
[27]. Of great interest, the 3′UTR of the OXTR gene
contains binding sites for seed sequences of microRNA-
21 and microRNA-451. OXTR is one of the main mo-
lecular pathways that regulate mammalian social behav-
ior [28], and genetic perturbations in OXTR have been
implicated in subpopulations of individuals with asd
[29], including Asperger’s syndrome [30]. There is an
eight-nucleotide seed sequence for microRNA-21,
starting at nucleotide 1079 of the 3′UTR of the OXTR
transcript, while there is an eight-nucleotide seed se-
quence for miR-451a at nucleotide 1755 of the same 3′
UTR (Fig. 4a). In order to experimentally determine if
these microRNAs may directly target the OXTR 3′
Fig. 3 Gene ontology analysis of predicted targets of miR-142-5p, miR-142-3p, miR-21-5p, miR-144-3p, and miR-451a. Gene ontology analysis was
performed by DIANA-lab software. Chart contains all gene ontology categories that are considered significant (adjusted p value <0.05)
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a plasmid that expresses the luciferase gene fused to
the 3′UTR of the OXTR mRNA. This plasmid was
cotransfected with a plasmid expressing GFP alone,
GFP and miR-21-5p, or GFP and miR-451a. Both miR-
21-5p and miR-451a induced a decrease in luciferase
luminescence, compared to transfections with GFP
alone (Fig. 4b). In a separate luciferase assay, we examined
if miR-21-5p and miR-451a downregulate luciferase expres-
sion, in comparison to a microRNA that does not target
OXTR, miR-7. In fact, miR-451a and miR-21-5p both sig-
nificantly decreased luciferase expression, in comparison to
miR-7 (Fig. 4c). This provides in vitro evidence that these
two microRNAs can target the OXTR gene.
To gain more insight into the relationship between these
microRNAs and OXTR expression, we performed real-time
PCR to detect the levels of OXTR mRNA in the human
brain samples. OXTR is significantly overexpressed in the
autism brain samples (Fig. 4c; p = 0.005). In a previous ana-
lysis of DNA methylation levels in these same brain sam-
ples, there were no differences in the methylation of the
OXTR gene, suggesting that the differences in OXTR gene
transcription are not related to methylation [6]. While the
increase of OXTR in the autism brain samples may not
be intuitive, this finding validates a previous study [31]
of increased OXTR expression in the frontal cortex of
autistic individuals. Pearson’s correlation analysis re-
veals that there is a direct positive correlation between
OXTR expression and the expression of microRNA-21
(Fig. 4d), but not miR-451a (Fig. 4e), in the brainsamples from the current study. Therefore, miR-21-5p
and OXTR expression is increasing in the same
individuals.
To determine the role of miR-451a and miR-21-5p in
the translation of oxytocin receptor protein, we performed
Western blot on the brain samples from our current
study. We detected two strong bands for OXTR at ap-
proximately 55 kD (Fig. 5a), consistent with previous find-
ings in human and monkey brain samples [32, 33]. It is
not currently clear in the literature whether these two
bands are due to different isoforms or post-translational
modifications. There was no significant difference in
OXTR protein levels between the control and autism
groups (Fig. 5b). This data is in contrast to our finding
that there are significantly increased levels of OXTR
mRNA in the autism brain and suggests that there may be
an inhibition of protein translation.
To understand if miR-21-5p and miR-451a may have a
role in inhibiting the translation of OXTR protein, we
determined the protein/mRNA ratio for each sample in
our analysis, and levels of miR-21-5p and miR-451a were
then correlated to the protein/mRNA ratio. This analysis
has previously been used to examine relationships be-
tween microRNA expression and protein translation
[34]. Of great interest, there is a significant negative cor-
relation between the expression of miR-21-5p (Fig. 5c),
but not miR-451a (Fig. 5d), and the OXTR protein/
mRNA ratio. This suggests that miR-21-5p may prevent
the translation of OXTR protein from the existing
mRNA in the human brain.
Fig. 4 miR-451a and miR-21-3p target OXTR 3′UTR, and miR-21-5p expression levels correlate with OXTR expression levels. a Schematic representation
of the 3′UTR of the OXTR mRNA, containing seed regions for miR-451a and miR-21-5p. b Luciferase assays assessing the effect of microRNA expression
on the 3′UTR of the OXTR transcript. Expression of either miR-451a or miR-21-5p led to a significant reduction in translation from the luciferase-3′UTR
OXTR transcript, compared to GFP expressing vector. *p value <0.05, **p value <0.01. Two-tailed t test. c Luciferase assay showing effect of miR-451a
and miR-21-5p on luciferase expression, in comparison to miR-7. *p value <0.05, **p value <0.01. One-tailed t-test. d Box and whisker plot of OXTR gene
expression levels in human brain, as assessed by real-time PCR. p = 0.0052 in two-tailed t-test. e, f Spearman’s correlation coefficient and respective
p value between miR-21-5p (d) or miR-451a (e) expression and OXTR gene expression. There is a significant positive correlation between miR-21-5p
expression and OXTR gene expression
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The findings of this study add to a growing literature ex-
ploring the molecular processes in the brain of individuals
diagnosed with asd. First, the finding that miR-142 upregu-
lation is significantly correlated with hypomethylation of
the gene promoter provides further evidence of the primary
role that epigenetics plays in mediation of gene expression
in the autism brain. Previous studies have determined dys-
regulation in DNA methylation patterns in the brain [35]
and lymphocytes [36] of humans with autism. Importantly,
DNA methylation dysregulation was correlated with aber-
rant gene expression [6]. This study provides evidence for
an additional mechanism for regulation of gene expression
by epigenetics, where DNA hypomethylation may increasemiR-142 expression, leading to possible secondary effects
on downstream targets.
MiR-142 has previously been implicated in regulating
proteins involved in neurotransmitter function. MiR-
142-5p downregulates the transcription of monoamine
oxidase A (MAOA) by decreasing the amounts of
sirtuin1, a transcription factor that is involved in the tran-
scription of MAOA [37]. MAOA metabolizes monamine
neurotransmitters, including serotonin, dopamine, and
noradrenaline. In addition, miR-142-3p targets and de-
creases the translation of D1 dopamine receptors [38].
Therefore, both miR-142-5p and miR-142-3p have im-
portant roles in the dopaminergic and monoamine path-
ways in the brain.
Fig. 5 miR-21-5p expression correlates with less OXTR protein translation from mRNA in the brain. a Western blot analysis of OXTR in the human brain
samples. Hsc70 is the endogenous control. b Quantitative analysis of relative OXTR protein levels in control and autism groups. OXTR levels were
normalized to Hsc70, and data is presented as relative quantity. p= 0.089 two-tailed t test. c, d Spearman’s correlation coefficient and respective p value
between miR-21-5p (c) and miR-451a (d) expression and the OXTR protein/mRNA ratio in each individual. a.u. signifies arbitrary units. There is a significant
negative correlation between miR-21-5p expression and OXTR protein/mRNA ratio in human brain samples
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of microRNAs may target neurotransmitter-related genes,
our study also identifies the oxytocin system as a target of
these microRNAs. The finding that the microRNAs that
can target OXTR are upregulated in the brain of individ-
uals with autism suggests that molecular pathways re-
sponsible for social behaviors are directly targeted by
microRNAs in the brain. Activation of OXTR by oxytocin
is considered one of the central biological signals for social
behavior. Oxytocin has been implicated in several social
behaviors [28], and several independent studies have
suggested that treatment of individuals with oxytocin
may improve social behaviors [39–41]. Single nucleotide
polymorphisms in OXTR gene have been significantly
correlated to autism in a meta-analysis [29] and have
also been correlated to Asperger’s syndrome in a separ-
ate study [30]. In addition, decreased plasma oxytocin
levels have been reported in individuals with asd [42].
While the role of OXTR specifically in the frontal cortex
has not been extensively studied, recent research deter-
mined a role for OXTR in sociosexual behavior in mice
[43]. Nonetheless, further research is needed to under-
stand the role of OXTR specifically in the frontal cortex.
The data from this research suggests an interesting
interaction between miR-21-5p expression, OXTR gene
expression, and OXTR protein translation. MicroRNAs
can affect protein translation by degradation of thetarget mRNA or by inhibiting translation [44]. miR-21-
5p expression positively correlated with OXTR mRNA
levels, suggesting that miR-21-5p does not induce deg-
radation of OXTR mRNA in our samples. Two recent
publications have also determined positive correlations
between microRNA expression in the brain and the ex-
pression levels of their target mRNAs [14, 45], including
in individuals with Huntington’s disease. Therefore, we
can postulate the existence of a positive feedback mech-
anism by which increased gene expression may induce
increased microRNA expression. However, the direction-
ality of this feedback mechanism is not clear. Of import-
ance, the finding that miR-21-5p expression is negatively
correlated with the OXTR protein/mRNA ratio suggests
that miR-21-5p can inhibit the translation of OXTR and
may be an important factor in limiting the levels of
OXTR in the human autism brain. However, it is still
problematic to conclude the function of miR-21-5p on
OXTR translation through correlation data alone. There-
fore, in order to strengthen and verify the conclusion that
miR-21-5p is a regulator of OXTR in the brain, it will be
necessary to induce an overexpression of miR-21-5p in the
mouse brain, either through transgenic or lentiviral infec-
tion, and probe its effects on OXTR levels. Nonetheless,
we may hypothesize that in the autism brain, attempts
to increase OXTR protein levels, and downstream social
behaviors, are being inhibited by miR-21-5p, thereby
Mor et al. Molecular Autism  (2015) 6:46 Page 10 of 11exacerbating the autism phenotype. Further in vivo
studies may shed light onto this hypothesis.
We note that miR-451a induced a stronger downregula-
tion of the OXTR 3′UTR activity in the luciferase assays,
while only miR-21-5p was correlated with OXTR expres-
sion in the human brain. We may offer two possible hy-
potheses for this discrepancy. One hypothesis is that the
structure of the coding region of the OXTR gene, which is
not present in the luciferase plasmid, may affect the effi-
ciency of microRNA regulation. A second hypothesis is that
miR-21-5p may be expressed at higher levels in cells that
express OXTR in the human brain. Since our brain samples
display cell type heterogeneity, we do not know which cell
types are expressing the microRNAs, and further experi-
mentation would be necessary to understand which micro-
RNAs are specifically expressed in OXTR expressing cells.
It is also worthy to note that the previous microarray study
of microRNAs in the autism brain identified increased
miR-21-5p in a subset of their autism brain samples [16].
A previous study looked at microRNAs in the serum of
individuals that were diagnosed with autism [15]. The
microRNAs found in our study are not overlapping with
those found in their study. However, both of our studies
uncovered microRNAs that target genes involved in axonal
guidance and TGF-beta signaling, according to the gene
ontology analysis. Therefore, microRNAs involved in these
pathways may be particularly sensitive to dysregulation in
autism, although there may be tissue specificity in the iden-
tity of which microRNAs are dysregulated.Conclusions
We present evidence that microRNA dysregulation occurs
in the brain of individuals diagnosed with autism spectrum
disorders and that the dysregulated microRNAs target
biological pathways and specific genes that are highly rele-
vant to the biology of autism, including the OXTR gene.
We also present evidence that microRNA overexpression
may be mediated by epigenetic changes, which is a rather
novel finding in the research of microRNAs in the brain.
Therefore, this study provides further evidence of a multidi-
mensional dysregulation of molecular mechanisms in the
brain of individuals diagnosed with asd, including interplay
between epigenetic mechanisms, microRNAs, and down-
stream mRNA targets.Additional files
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